Molecules

FAP-2286

Target FAPClass Cyclic peptide (DOTA chelator)

6ongoing trials
2radiolabelled forms
0approved products
91publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C67H99N13O18S3
Molar mass (g/mol)
1,470.8
Exact mass (Da)
1,469.6393
XLogP
-8.1
H-bond donors
12
H-bond acceptors
25
Rotatable bonds
25
Heavy atoms
101
InChIKey
UHKLVUPDBJFFBB-ZCDGVBLYSA-N
PubChem record
CID 163408889 ↗
IUPAC name
(5R,11S,17S,20S,23S,26S,29R)-23-(3-amino-3-oxopropyl)-26-benzyl-5-(hexanoylamino)-20-[(1R)-1-hydroxyethyl]-6,12,18,21,24,27-hexaoxo-35-[2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]ethylsulfanylmethyl]-3,31-dithia-7,13,19,22,25,28-hexazatetracyclo[31.3.1.07,11.013,17]heptatriaconta-1(37),33,35-triene-29-carboxylic acid
SMILES
CCCCCC(=O)N[C@H]1CSCC2=CC(=CC(=C2)CSCCNC(=O)CN3CCN(CCN(CCN(CC3)CC(=O)O)CC(=O)O)CC(=O)O)CSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]4CCCN4C(=O)[C@@H]5CCCN5C1=O)[C@@H](C)O)CCC(=O)N)CC6=CC=CC=C6)C(=O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁷⁷Lu]Lu-FAP-2286 Syntheses and QC ↗Therapy—3Phase 2—
[⁶⁸Ga]Ga-FAP-2286 Syntheses and QC ↗Imaging—3Phase 2—

Ongoing trials · 6Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
LuMIERE · [177Lu]FAP-2286NCT04939610 · Solid tumors (multiple indications)Phase 2RecruitingNovartis Pharmaceuticals6
FAP ligands (FAPI)NCT07523607 · BreastPhase 2Not yet recruitingOdense University Hospital0
Lu-FAP CUP · [177Lu]FAP-2286NCT07434180 · Solid tumors (multiple indications)Phase 2Not yet recruitingPeter MacCallum Cancer Centre, Australia1
FAUNUS · [177Lu]FAP-2286NCT06880757 · Bladder / urothelialPhase 2Not yet recruitingAnkara University0
FAP ligands (FAPI)NCT04621435 · Solid tumors (multiple indications)Phase 1RecruitingThomas Hope1
FAP ligands (FAPI)NCT07144085 · Solid tumors (multiple indications)Phase 1RecruitingYi Tian1

Published results · 1

2026-09LuMIERE (phase 1) · earlyWell tolerated up to 9.25 GBq, chosen for phase 2, but only one partial response in 27 patients: the activity of FAP targeting remains to be shown.Clin Cancer Res ↗

PublicationsAll publications in PubMed ↗

91 publications in PubMed for the query below; the most recent:

"FAP-2286"[tiab]

  1. 177 Lu-FAP-2286 Targeted Radionuclide Therapy in Advanced Pancreatic Cancer : A Real-World Retrospective Salvage Study Clin Nucl Med, 2026
  2. A Favorable Partial Response in Patients With Glioblastoma Multiforme Following Combined [177Lu]Lu-FAP-2286 and Chemotherapy Clin Nucl Med, 2026
  3. Heterobivalent fibroblast activation protein-targeted Radiotheranostic ligands integrating cyclic peptide and small-molecule motifs for enhanced tumor retention Bioorg Chem, 2026
  4. Novel Covalent FAP-Targeted Radiotherapy Drug Based on DOTA-FAP-2286 for Enhanced Tumor Uptake, Retention, and Therapeutic Efficacy Mol Pharm, 2026
  5. FAP-targeted [(177)Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer Nucl Med Biol, 2026
  6. Combined 177Lu-FAP-2286 Therapy and Chemotherapy in Extraskeletal Ewing Sarcoma With Multiple Metastases Clin Nucl Med, 2026
  7. Combined 177 Lu-FAP-2286 Therapy and Immunotherapy in Metastatic Esophageal Squamous Cell Carcinoma Clin Nucl Med, 2026
  8. 177 Lu-FAP-2286 Therapy in a Patient of Advanced Metastatic Malignant Solitary Fibrous Tumor Clin Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

FAP-2286. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fap-2286/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.